NICE Archives - Page 6 of 46 -

Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis

NICE says yes to Novartis’ Rydapt for rare blood disorder

https://pharmaphorum.com/news/nice-says-yes-to-novartis-rydapt-for-rare-blood-disorder/

Market Access/ Views & Analysis/ Views and analysis

A problem combination?

Leela Barham combination therapies, NHS, NICE 0 Comment

Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge

A problem combination?

https://pharmaphorum.com/views-and-analysis/a-problem-combination/

Market Access/ News/ News

NICE changes stance on Lilly’s breast cancer dug Verzenios

Phil Taylor breast cancer, Eli Lilly, NHS, NICE, Oncology, Verzenio 0 Comment

After rejecting Eli Lilly’s Verzenios for breast cancer therapy earlier this year, NICE has relented, recommending the drug

NICE changes stance on Lilly’s breast cancer dug Verzenios

https://pharmaphorum.com/news/nice-changes-stance-on-lillys-breast-cancer-dug-verzenio/

Market Access/ News/ News

Scotland backs Bavencio for bladder cancer after NICE says no

Phil Taylor Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer, Scotland, Scottish Medicines Consortium, urothelial carcinoma 0 Comment

Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance

Scotland backs Bavencio for bladder cancer after NICE says no

https://pharmaphorum.com/news/scotland-backs-bavencio-for-bladder-cancer-after-nice-says-no/

Patients/ Views & Analysis/ Views and analysis

How to balance the patient voice atop the shifting plates of HTA

Amanda Barrell ABPI, HTA, NICE 0 Comment

The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit

How to balance the patient voice atop the shifting plates of HTA

https://pharmaphorum.com/views-and-analysis/how-to-balance-the-patient-voice-atop-the-shifting-plates-of-hta/

Market Access/ News/ News

UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme

Phil Taylor bimekizumab, dermatology, HEOR, NICE, psoriasis, UCB 0 Comment

UCB’s bimekizumab hasn’t been approved for marketing in Europe yet, but has already been given the nod for

UCB’s bimekizumab ‘pre-approved’ using NICE fast-track scheme

https://pharmaphorum.com/news/ucbs-bimekizumab-pre-approved-using-nice-fast-track-scheme/

Market Access/ News/ News

NICE changes its mind on rare bile duct cancer drug from Incyte

Phil Taylor cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology 0 Comment

Incyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer,

NICE changes its mind on rare bile duct cancer drug from Incyte

https://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/

News/ News/ Oncology

NICE’s second Zytiga rejection ‘shows need for flexible pricing models’

Phil Taylor Johnson & Johnson, NICE, Oncology, Prostate cancer, The Institute of Cancer Research, Zytiga 0 Comment

NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a

NICE’s second Zytiga rejection ‘shows need for flexible pricing models’

https://pharmaphorum.com/news/nice-second-zytiga-rejection-shows-need-for-flexible-pricing-models/

Market Access/ Views & Analysis/ Views and analysis

NICE feedback?

Leela Barham NICE 0 Comment

The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review

NICE feedback?

https://pharmaphorum.com/views-and-analysis/nice-feedback/

Trending

NICE

Login